Journal News

How mucus keeps us healthy

Leia Dwyer
April 11, 2023

We tend to associate mucus with colds and flu, but its role in the body is complex and varied. This colloidal network of salts, enzymes, antibodies, glycans and glycoproteins is found in the nose, mouth, lungs, stomach, intestines and reproductive tract. The slimy mucus layer of the stomach includes bottle brush–shaped glycoproteins called mucins that contain carbohydrate chains called glycans that help build a selective, viscous barrier between epithelial cells and the external environment.

Sara Lindén at the University of Gothenburg in Sweden studies interactions between microbes and mucosal surfaces in the stomach, intestine and airways. “Until relatively recently many researchers thought the role of the glycans on the mucins was merely to hold water and thereby create a lubricating barrier on our mucosal surfaces,” Lindén said. “Recently, a number of studies have shown that the mucin glycans have roles in binding to and governing interactions with microbes, including both the natural commensal microflora and disease-causing microbes.”

This cartoon shows green Helicobacter pylori associating with diverse glycans (red, yellow and blue) in mucus of the stomach.
Lindén et al./MCP
This cartoon shows green Helicobacter pylori associating with diverse glycans (red, yellow and blue) in mucus of the stomach.

Helicobacter pylori is a common bacteria that can cause harmful infection. Spread through contaminated drinking water, poor sanitation and saliva sharing, it might be present in as much as 50% of the world’s population. Most people are unaffected, but some experience stomach pain and develop ulcers. Chronic infection can lead to certain stomach cancers, and many strains of H. pylori are now antibiotic resistant.

Lindén’s doctoral studies involved H. pylori interactions in the human stomach, and she has continued this line of research. A recent article in the journal Molecular & Cellular Proteomics reports on novel glycan structures her team found in mucin from stomach samples of individuals with and without H. pyloriinfection.

The lab’s previous studies showed people benefit from mucins that bind efficiently to Helicobacter, as this limits the bacteria that come into contact with human cells and cause disease. Proteins on the H. pylori surface called adhesins bind to surface structures on the cell, Lindén explained. “Mucins can also bind to these adhesins and act as releasable decoys that Helicobacter can bind to instead of the human cell.”

Lindén and her team were surprised at the diversity they found in over 600 carbohydrate structures identified from just 28 patient samples. Patients infected with H. pylori showed larger interpatient variability in this diversity than noninfected patients. In this context, Lindén said, “The high diversity of glycans suggests that interactions with microbes in the stomach can vary enormously between different individuals.”

Previous experiments in animals have shown that H. pyloriinfection and mucin production are cyclically related: Infection leads to decreased mucin production as well as changes in the mucin glycosylation, allowing more H. pylori to bind cells and infect. In this study, Lindén’s team found specific structures that correlated particularly well to H. pylori binding.

All this could inform the design of glycan-based therapeutics as an alternative to the standard use of multiple antibiotics. Gurdeep Chahal, lead author of this article, imagines that “targeting the H. pylori adhesins with the analogues of these glycans could reduce the bacterial colonization in the stomach while simultaneously treating chronic gastritis.”

Lindén sees the results going further: “The work presented here shows how structures in the human body differ between individuals and how this affects interactions with a pathogen … part of a larger concept of understanding how our body surfaces defend themselves against disease causing microorganisms and how we can enhance these defense systems to treat and prevent infections without antibiotics.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Leia Dwyer

Leia Dwyer is a Boston-area biotech and pharmaceutical industry professional.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Computational tool helps scientists create novel bug sprays
Journal News

Computational tool helps scientists create novel bug sprays

May 20, 2025

Rapid discovery of mosquito repellent compounds is enabled through a novel screening platform that combines both computational modeling and functional screening.

Meet Lan Huang
Interview

Meet Lan Huang

May 19, 2025

Molecular & Cellular Proteomics associate editor uses crosslinking mass spec to study protein–protein interactions to find novel therapeutics.

Influenza gets help from gum disease bacteria
Journal News

Influenza gets help from gum disease bacteria

May 15, 2025

Scientists discover that a protease from Porphyromonas gingivalis enhances viral spread. Read more about this recent Journal of Biological Chemistry paper.

How bacteria fight back against promising antimicrobial peptide
Journal News

How bacteria fight back against promising antimicrobial peptide

May 15, 2025

Researchers find a mutation in E. coli that reduces its susceptibility to a potential novel antibiotic. Read more about this recent Journal of Biological Chemistry paper.

New clues reveal how cells respond to stress
Journal News

New clues reveal how cells respond to stress

May 15, 2025

Redox signaling protein may help regulate inflammasome and innate immune activation. Read more about this recent Journal of Biological Chemistry paper.

Innovative platform empowers scientists to transform venoms into therapeutics
Journal News

Innovative platform empowers scientists to transform venoms into therapeutics

May 13, 2025

Scientists combine phage display and a “metavenome” library to discover new drugs that bind clinically relevant human cell receptors. Read about this recent Molecular & Cellular Proteomics paper.